Statement

As reported by M/s. Abbott Labs. the details of products and value of exports during 1st September, 1984 to 31st October, 1985 are given below

PRODUCTS COVERED UNDER RE-ENDORSEMENT OF CAPACITY

	Name of the Product	Value (FOB) (Rs.)
1.	Cecon	46,777
2.	Erythrocin Granules	7,66,031
3.	Iberol Tablets (100's bottle)	90,323
4.	Iberol Tablets (25's bottle)	40,620
5.	Iberol '500' Tonic (90 ml. bottle)	24,281
6.	Kaltin with Neomycin	3,12,450
7.	Selsun 1%	8,34,644
8.	Selsun 2-1/2%	5,25,184
9.	Surbex T Tab. (100 ' bottle)	45,080
10.	Surbex T Tab. (25's bottle)	14,236
11.	Vidaylin-M Syrup (90 ml. bottle)	3,75,166
12.	Vidaylin-M Syrup (240 ml. bottle)	1,29,902
13.	Vidaylin-M Drops (15 ml. bottle)	90,618

PRODUCTS NOT COVERED UNDER RE-ENDORSEMENT OF CAPACITY

1.	Citrosoda	2,11,303
2.	Kaolin Mixture with Pectin	1,54,786
3.	Pentothal Sodium 1·0 gm.	5,35,224
4.	Pentothal Sodium 0·5 gm.	47,983

Production of bulk drugs by foreign companies

2200. SHRI SYED RAHMAT ALI: Will the Minister of INDUSTRY be pleased to refer to answer to Unstarred Question 195 given in the Rajya Sabha on the 18th November 1985 and state:

(a) whether it is a fact that Government have respected the recommendation of Hathi Committee for production of bulk drugs from basic stages within a period of two years by foreign companies which they were importing or producing from intermediate stages during 1978;

(b) whether it is a fact that such provision is covered under Drug Policy, 1978; and

(c) if so, what steps were taken to implement this provision?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) and (b) The Government have accepted the recommendation of the Hathi Committee that foreign comapnies producing bulk drugs from penultimate stage will have to manufacture the same from the basic stage within a period of two years.

(c) In the absence of any provision under the I (D&R) Act, 1951 to call back the existing industrial licences and impose fresh conditions thereon, the policy decision contained in paragraph

21 of the 1978 Drug could not be implemented fully.

Categorisation of PAS and its salts

2201. SHRI NAND KISHORE BHATT: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 185 given in the Rajya Sabha on the 18th November, 1985 and state:

(a) whether it is a fact that PAS and its salts have been categorised as essential drugs and the same fall under Category I of Drugs Price Control Order;

(b) what are the reasons for shortfall of production of this drug by Pfizer;

(c) names of other drugs which fall in category I and II for which Pfizer has been licensed to produce along with permitted capacity of each and production during the last three years, yearwise;

(d) what is the percentage of total sales turn over of category I and II drugs during the last three years, yearwise of this company;

(e) whether it is also a fact that Pfizer is over producing those drug and formulations which either fall under exempted category or where the company is overcharging the prices; and

(f) if so, what are the details thereof?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) PAS and its salts with the exception of Calcium B PAS fall under Category I of the Drugs (Prices Control) Order, 1979.

(b) There is overall decline in the demand of PAS and its salts on account of availability of newer drugs for treatment of Tuberculosis.

(c) Information to the extent available is given in the attached Statement (*See below*).

(d) Information as available is given below:—

Year	Sales value of Category I and II formulations excluding excise duty, but, including sales tax as a percentage of total sale turnover of formulations
Ending November, 1982	42.34
Ending November, 1983	40.39
Ending November, 1984	39.85

(e) and (f) Each company tailors its production to market demand. M|s. Pfizer Limited are marketing certain formulations based on Oxytetracycline, and Vitamins at the pre-revised prices based on the stay|Orders of the High Court.

Statement

Sl No	Name of the Bulk Drug	Category	Licensed capacity (tonnes)	Production 1982-83	1983-84	1984-85
1.	Oxytetracycline and its salts	II	9	69.85	84.49	86.40
2.	Tetracycline	II	5	Nil	Nil	Nil
3.	INH	I	80	72.92	86.56	80.01